Characteristics of the protective action of alpha-Tocopherol in vascular hypoxia.
The functioning of the guinea-pig isolated portal vein was monitored by measuring spontaneous mechanical activity, responses to electrical stimulation and administered noradrenaline in normoxic conditions. The effect of hypoxia, induced by bubbling the physiological bathing solution with a 95% N(2)/5% CO(2) gas mixture, on the mechanical performance of the vein was then assessed. Spontaneous activity declined in hypoxia, with mean contraction tension reduced by 55 + or - 8.8%. The responses to electrical field stimulation (2-32 Hz, 0.7 msec. 70 V) were lowered by 14 + or - 4.6% but contractions produced by a range of noradrenaline concentrations (0.01-160 mu M) were unaffected by hypoxia. Substitution of glucose in the bathing solution with sucrose, a substrate unavailable to the cells for energy generation, produced a marked enhancement of the effect of hypoxia. Spontaneous activity was reduced by 76 + or - 8.3%, electrically-induced activity by 80 + or - 14.4% and noradrenaline-induced responses by 85 + or - 6.8%. Although in normoxia the activity and responses of the portal vein were unaffected by the presence of alpha-tocopherol, it significantly protected the functioning of the vein in hypoxic conditions. This effect was concentration-dependent within the range 10-160 mu M and was most marked when glucose was replaced by sucrose in the bathing solution.
Kelly
M J
MJ
Health Sciences Group, Leeds Metropolitan University, United Kingdom.
Richardson
W
W
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000818:Animals; D004558:Electric Stimulation; D004734:Energy Metabolism / Q000187:drug effects; D005260:Female; D006168:Guinea Pigs; D000860:Hypoxia / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D009638:Norepinephrine / Q000378:metabolism / Q000494:pharmacology; D011169:Portal Vein / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D014810:Vitamin E / Q000627:therapeutic use*
D000316:Adrenergic alpha-Agonists; D014810:Vitamin E; D009638:Norepinephrine